Zaprinast
Top View
- British Journal of Nutrition (2014), 112, 1427–1437 Doi:10.1017/S0007114514002232 Q the Authors 2014
- Roflumilast Ameliorates Cognitive Impairment in APP/PS1 Mice Via Camp/CREB/BDNF Signaling and Anti-Neuroinflammatory Effects
- Modulation of High Affinity ATP-Dependent Cyclic Nucleotide
- Pharmaabkommen A1 E
- Rhobtb1 Protects Against Hypertension and Arterial Stiffness by Restraining Phosphodiesterase 5 Activity
- New Drugs Review Thorax: First Published As 10.1136/Thx.46.7.512 on 1 July 1991
- Customs Tariff - Schedule Xxi - 1
- PDE5 Inhibitors Beyond Erectile Dysfunction
- Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
- A Full Cycle Anti-Viral Drug Screen Identifies a Clinical Compound
- BAY 41-2272 Attenuates CTGF Expression Via Sgc/Cgmp-Independent Pathway in Tgfβ1-Activated Hepatic Stellate Cells
- Phenotypic, Chemical and Functional Characterization of Cyclic Nucleotide Phosphodiesterase 4 (PDE4) As a Potential Anthelmintic Drug Target
- (51) International Patent Classification: (74) Agent: HARRIS, Bob Et Al.; Viksnins Flarris Padys Malen A61K 31/4725 (2006.01) A6
- The Phosphodiesterase 5 Inhibitor Tadalafil Regulates Lipidic
- Epimedium Icariin
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Zaprinast, a Well-Known Cyclic Guanosine Monophosphate-Specific
- Inhibitors Phosphodiesterase (PDE)